Tirzepatide is a once-weekly subcutaneous injection developed by Eli Lilly and Company. It is the first dual incretin agonist — activating both GLP-1 and GIP receptors. SURMOUNT-1 demonstrated 22.5% mean body weight loss at the 15 mg dose over 72 weeks, the highest weight loss reported for any approved or investigational GLP-1 medication.
Tirzepatide is a once-weekly subcutaneous injection developed by Eli Lilly and Company. It is the first dual incretin agonist — activating both GLP-1 and GIP receptors. SURMOUNT-1 demonstrated 22.5% mean body weight loss at the 15 mg dose over 72 weeks, the highest weight loss reported for any approved or investigational GLP-1 medication.
Manufacturer / source: Mounjaro, Zepbound, compounded
For tirzepatide forms head-to-head, see comparison page. For trial data, see clinical research.
Compounded semaglutide + tirzepatide · MD/DO oversight
*12-month plan · flat rate · all titration doses
Or call (949) 818-8000